GYNECOLOGIC CANCERS

In patients with persistent, recurrent, or metastatic cervical cancer the addition of pembrolizumab to chemotherapy with or without bevacizumab significantly improved survival and response rates.

High responses to single-agent dostarlimab-gxly were seen in patients with endometrial cancer who had a high tumor mutational burden, irrespective of mismatch repair or microsatellite stability status.

The first patient with a locally advanced or metastatic solid tumor has been dosed with buparlisib in combination with A0025 with or without atezolizumab in a phase 1a clinical trial.

In an interview with Targeted Oncology, Melissa K. Frey, MD, discussed findings from implementing web-based health information collection of family history in patients with gynecologic cancers.

In an interview with Targeted Oncology™, Isabelle Ray-Coquard, MD, PhD, discussed the NEOPEMBROV study in greater detail and the benefits of adding pembrolizumab to perioperative treatment for serous carcinoma deemed non-optimally resectable.

In an interview with Targeted Oncology™, Shannon N. Westin, MD, MPH, FACOG, discussed the need for the DUO-E trial in the endometrial cancer space and the unique patient population the study will evaluate.

Shannon Westin, MD, MPH, FACOG, a gynecologic oncologist at The University of Texas MD Anderson Cancer Center, discusses the use of durvalumab with or without olaparib for the treatment of endometrial cancers.

The FDA has accepted a new supplemental biologics license application for pembrolizumab, an anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, who have diseased progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Following the success of a phase 1 study that showed its potential for accelerated FDA approval in the future, the WEE-1 inhibitor, ZN-c3 has been dosed for the first time in the newly launched phase 2 study, which is exploring the agent for the treatment of adult women with recurrent or persistent uterine serous carcinoma.

In an interview with Targeted Oncology™, Shannon N. Westin, MD, MPH, FACOG, discussed the DUO-E trial, its design, end points, and the need for novel endometrial cancer therapies. 

In an interview with Targeted Oncology, Bobbie J. Rimel, MD, discussed the phase 2 NRG-GY012 results and the next step for cediranib plus olaparib as treatment of recurrent or metastatic endometrial cancer.

In an interview with Targeted Oncology, Melissa M. Hardesty, MD, explained the state of gynecologic oncology treatment for rural patients in Alaska and how research is finding answers for improving clinical outcomes.

In an interview with Targeted Oncology, Bradley Monk, MD, FACCOG, FACS, discusses the OUTBACK trial, including the results, strengths, and challenges.

The FDA has approved the combination of lenvatinib and pembrolizumab for the treatment of patients with advanced endometrial cancer that is not microsatellite instability–high or mismatch repair deficient, who have disease progression following prior systemic treatment and who are not candidates for curative surgery or radiation.

In an interview with Targeted Oncology, Eugene Ahn, MD, reviewed the data from the uterine cancer cohort of the TAPUR study and explained the implications of the findings.

Maurie Markman, MD, addresses different treatment options, including checkpoint inhibitors, for patients with endometrial cancer.

The combination of the anti-PD-1/PD-L1 therapy pembrolizumab with the platinum-based chemotherapy regimens paclitaxel plus cisplatin or paclitaxel plus carboplatin administered with or without bevacizumab improved both progression-free and overall survival in patients with persistent, recurrent, or metastatic cervical cancer, meeting the primary end point of the phase 3 KEYNOTE-826 trial.

The FDA has accepted the biologics license application for the anti-PD-1 antibody drug balstilimab for the treatment of recurrent of metastatic cervical cancer with disease progression on or after chemotherapy.

In an interview with Targeted Oncology, held during the 2021 ASCO Annual Meeting, Travis Sims, MD, MPH, discussed the treatment of HRD-positive ovarian cancer and the retrospective analysis of HRD status and its impact of survival outcomes for this patient population.

In patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer, the combination of pertuzumab and trastuzumab led to a 37% disease control rate, according to results from the Targeted Agent Profiling and Utilization Registry study.

In women with locally advanced cervical cancer, administering adjuvant chemotherapy following standard cisplatin-based chemoradiation did not improve survival outcomes, according to findings from the phase 3 OUTBACK trial.

In an interview with Targeted Oncology following the medical conference presentation, Ritu Salani, MD, expanded on the role biomarkers play in the treatment of cervical cancer, how this testing looks in the everyday clinics, and how it can potentially change pending competition of ongoing clinical trials.

For the past 17 years, HPV-related cervical cancer has been declining, however, other tumors related to the virus continue to remain steady.

Annelise Wilhite, MD, discusses a clinical investigation of survival in patients with vulvar/vaginal melanomas.

The FDA has granted priority review to 2 supplemental new drug applications for the combination use of pembrolizumab and lenvatinib.

In an interview with Targeted Oncology, Ursula A. Matulonis, MD, discusses results from further follow-up of patients with ovarian cancer treated in the ENGOT-OV16/NOVA.

Here is a look back at the FDA happenings from the month of April 2021.

A leader in gynecologic oncology, Chirag Shah, MD, MPH, provides insight into the future of ovarian cancer by discussing the potential for immunotherapy, TP53 inhibition, and novel therapeutics on the horizon.

Chirag Shah, MD, MPH, discusses platinum sensitivity vs resistance impact treatment selection in subsequent lines of therapy.

An expert in gynecologic oncology reviews the PRIMA and NOVA clinical trials and discusses their implications for the management of ovarian cancer.